These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 18927314)
1. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Tse AN; Klimstra DS; Gonen M; Shah M; Sheikh T; Sikorski R; Carvajal R; Mui J; Tipian C; O'Reilly E; Chung K; Maki R; Lefkowitz R; Brown K; Manova-Todorova K; Wu N; Egorin MJ; Kelsen D; Schwartz GK Clin Cancer Res; 2008 Oct; 14(20):6704-11. PubMed ID: 18927314 [TBL] [Abstract][Full Text] [Related]
2. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127 [TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239 [TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531 [TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584 [TBL] [Abstract][Full Text] [Related]
6. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552 [TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532 [TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709 [TBL] [Abstract][Full Text] [Related]
10. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374 [TBL] [Abstract][Full Text] [Related]
11. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Iyer G; Morris MJ; Rathkopf D; Slovin SF; Steers M; Larson SM; Schwartz LH; Curley T; DeLaCruz A; Ye Q; Heller G; Egorin MJ; Ivy SP; Rosen N; Scher HI; Solit DB Cancer Chemother Pharmacol; 2012 Apr; 69(4):1089-97. PubMed ID: 22124669 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116 [TBL] [Abstract][Full Text] [Related]
14. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors. Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606 [TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623 [TBL] [Abstract][Full Text] [Related]
16. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. Martin LK; Bekaii-Saab T; Serna D; Monk P; Clinton SK; Grever MR; Kraut EH Onkologie; 2013; 36(11):657-60. PubMed ID: 24192770 [TBL] [Abstract][Full Text] [Related]
17. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Fujii Y; Kato T; Kubota N; Fujimori A; Niwa O; Okayasu R Oncol Rep; 2010 Jan; 23(1):199-203. PubMed ID: 19956882 [TBL] [Abstract][Full Text] [Related]
18. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678 [TBL] [Abstract][Full Text] [Related]
19. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823 [TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]